Overview

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

Status:
Active, not recruiting
Trial end date:
2024-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company